In Vitro Fertilization Market Outlook 2026-2031: Rising Infertility Rates & Advancements in Assisted Reproductive Technologies Drive Global Market Growth, Says Mordor Intelligence

Mordor Intelligence projects the global in vitro fertilization (IVF) market will grow from $30.90B in 2026 to $45.90B by 2031, a CAGR of 8.28%, driven by rising infertility and greater adoption of assisted reproductive technologies. The report highlights tech adoption (AI-assisted embryo assessment, time-lapse imaging, genetic testing) and expanding clinic access and medical tourism, supporting demand growth especially in Asia-Pacific. Overall, the piece is constructive for fertility technology and services providers, but it is market-research/industry outlook rather than a specific company earnings catalyst.

Analysis

This reads as a long-duration demand signal, not a near-term earnings catalyst. The investable takeaway is that IVF growth should accrue first to recurring consumables, media, cryopreservation and lab workflow providers, while standalone equipment exposure is more cyclical and easier to over-earn on early optimism. For FUJIY and MKKGY, the addressable opportunity is real but likely a rounding error at the consolidated level unless IVF becomes a materially larger share of segment mix; the market should focus on whether this translates into durable pricing or just unit growth.

The second-order winner is likely the supplier with the highest consumables attach rate and the stickiest installed base, because rising procedure volumes compound after the initial instrument sale. AI-assisted embryo selection also creates a subtle margin shift: software-enabled workflow can improve clinic throughput, but it can also compress hardware differentiation over time, making reagent/consumable franchises relatively more attractive than instrument-only businesses. Cross-border fertility tourism should disproportionately benefit low-cost, globally distributed supply chains and local clinic networks in APAC, but that is a slower burn than the headline CAGR suggests.

The main risk is that the report’s growth assumptions do not convert into public-equity upside if reimbursement tightens, regulation around genetic testing/pGT becomes more restrictive, or consumers delay treatment in a weaker macro. The consensus may be overpaying for a theme that is mostly captured by private clinics and fragmented local operators rather than the named public parents. If segment disclosures over the next 1-2 quarters do not show above-trend organic growth, this thesis should be treated as a watch item rather than a trade.

Key Decisions for Investors

• No immediate aggressive trade: treat the IVF theme as a 6-18 month monitoring item; avoid chasing FUJIY or MKKGY solely on this report absent segment-level acceleration or margin uplift.
• If accumulating exposure, prefer MKKGY on pullbacks versus FUJIY for a 6-12 month horizon: Merck’s broader life-science/tools exposure gives better optionality to recurring lab consumables if IVF volumes compound, with lower single-theme risk.
• Use an alert-based trigger: only get constructive if either company shows double-digit organic growth in the relevant fertility/life-science line item or raises guidance tied to fertility consumables; otherwise assume the market has already priced the TAM story.
• Contrarian pair idea for a small basket: long MKKGY / short a broad healthcare ETF only if you want modest thematic exposure with lower beta; stop out if the fertility-related segment fails to beat mid-single-digit growth for two consecutive quarters.